A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism

Molecular Metabolism

Volumn 6, Issue 1, 2017, Pages 14-21

  Fisher, ffolliott M ^a   Kim, MiSung ^a   Doridot, Ludivine ^a   Cunniff, Jeremy C ^a   Parker, Thomas S ^b   Levine, Daniel M ^b   Hellerstein, Marc K ^c,d   Hudgins, Lisa C ^b   Maratos Flier, Eleftheria ^a   Herman, Mark A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ChREBP; FGF21; Fructose; Lipogenesis; NAFLD

Indexed keywords

CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN; FAT; FIBROBLAST GROWTH FACTOR 21; FRUCTOSE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; FIBROBLAST GROWTH FACTOR; MLXIPL PROTEIN, HUMAN; MLXIPL PROTEIN, MOUSE; NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE INTAKE; CELL ACTIVATION; CONTROLLED STUDY; FEEDING; FEMALE; FRUCTOSE METABOLISM; GENE TARGETING; GENETIC CONSERVATION; GLYCOLYSIS; HEPATIC STELLATE CELL; HUMAN; KNOCKOUT MOUSE; LIPOGENESIS; LIVER ATROPHY; LIVER FIBROSIS; LIVER METABOLISM; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; LIVER; LIVER CELL; MALE; METABOLISM;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; FEMALE; FIBROBLAST GROWTH FACTORS; FRUCTOSE; GLYCOLYSIS; HEPATOCYTES; HUMANS; LIPOGENESIS; LIVER; MALE; MICE; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85007579292     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.11.008     Document Type: Article

References (35)

1. [1] Bray, G.A., Nielsen, S.J., Popkin, B.M., Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. American Journal of Clinical Nutrition 79:4 (2004), 537–543.
2. [2] Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313:22 (2015), 2263–2273.
3. [3] Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Blendis, L., Halpern, Z., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. Journal of Hepatology 47:5 (2007), 711–717.
4. [4] Ma, J., Fox, C.S., Jacques, P.F., Speliotes, E.K., Hoffmann, U., Smith, C.E., et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. Journal of Hepatology 63:2 (2015), 462–469, 10.1016/j.jhep.2015.03.032.
5. [5] Stanhope, K.L., Schwarz, J.M., Keim, N.L., Griffen, S.C., Bremer, A.A., Graham, J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. Journal of Clinical Investigation 119:5 (2009), 1322–1334.
6. [6] Schwarz, J.M., Noworolski, S.M., Wen, M.J., Dyachenko, A., Prior, J.L., Weinberg, M.E., et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. Journal of Clinical Endocrinology and Metabolism 100:6 (2015), 2434–2442.
7. [7] Hudgins, L.C., Parker, T.S., Levine, D.M., Hellerstein, M.K., A dual sugar challenge test for lipogenic sensitivity to dietary fructose. Journal of Clinical Endocrinology and Metabolism 96:3 (2011), 861–868.
8. [8] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 115:5 (2005), 1343–1351.
9. [9] Lambert, J.E., Ramos-Roman, M.A., Browning, J.D., Parks, E.J., Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146:3 (2014), 726–735.
10. [10] Mayes, P.A., Intermediary metabolism of fructose. American Journal of Clinical Nutrition 58:5 Suppl (1993), 754S–765S.
11. [11] Stanhope, K.L., Schwarz, J.M., Havel, P.J., Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Current Opinion in Lipidology 24:3 (2013), 198–206.
12. [12] Kim, M.S., Krawczyk, S.A., Doridot, L., Fowler, A.J., Wang, J.X., Trauger, S.A., et al. ChREBP regulates fructose-induced glucose production independently of insulin signaling. Journal of Clinical Investigation 126:11 (2016 Nov 1), 4372–4386.
13. [13] Iizuka, K., Bruick, R.K., Liang, G., Horton, J.D., Uyeda, K., Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proceedings of the National Academy of Sciences of the United States of America 101:19 (2004), 7281–7286.
14. [14] Herman, M.A., Samuel, V.T., The sweet path to metabolic demise: fructose and lipid synthesis. Trends in Endocrinology and Metabolism 27:10 (2016 Oct), 719–730.
15. [15] Badman, M.K., Pissios, P., Kennedy, A.R., Koukos, G., Flier, J.S., Maratos-Flier, E., Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metabolism 5:6 (2007), 426–437.
16. [16] Kharitonenkov, A., Shiyanova, T.L., Koester, A., Ford, A.M., Micanovic, R., Galbreath, E.J., et al. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 115:6 (2005), 1627–1635.
17. [17] Markan, K.R., Naber, M.C., Ameka, M.K., Anderegg, M.D., Mangelsdorf, D.J., Kliewer, S.A., et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes 63:12 (2014), 4057–4063.
18. [18] Kharitonenkov, A., DiMarchi, R., FGF21 revolutions: recent advances illuminating FGF21 biology and medicinal properties. Trends in Endocrinology and Metabolism 26:11 (2015), 608–617.
19. [19] Potthoff, M.J., Inagaki, T., Satapati, S., Ding, X., He, T., Goetz, R., et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proceedings of the National Academy of Sciences of the United States of America 106:26 (2009), 10853–10858.
20. [20] Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metabolism 5:6 (2007), 415–425.
21. [21] Kim, H., Mendez, R., Zheng, Z., Chang, L., Cai, J., Zhang, R., et al. Liver-enriched transcription factor CREBH interacts with peroxisome proliferator-activated receptor alpha to regulate metabolic hormone FGF21. Endocrinology 155:3 (2014), 769–782.
22. [22] Park, J.G., Xu, X., Cho, S., Hur, K.Y., Lee, M.S., Kersten, S., et al. CREBH-FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis. Scientific Reports, 6, 2016, 27938.
23. [23] Dushay, J., Chui, P.C., Gopalakrishnan, G.S., Varela-Rey, M., Crawley, M., Fisher, F.M., et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:2 (2010), 456–463.
24. [24] Christodoulides, C., Dyson, P., Sprecher, D., Tsintzas, K., Karpe, F., Circulating fibroblast growth factor 21 is induced by peroxisome proliferator-activated receptor agonists but not ketosis in man. Journal of Clinical Endocrinology and Metabolism 94:9 (2009), 3594–3601.
25. [25] Galman, C., Lundasen, T., Kharitonenkov, A., Bina, H.A., Eriksson, M., Hafstrom, I., et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metabolism 8:2 (2008), 169–174.
26. [26] Sanchez, J., Palou, A., Pico, C., Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. Endocrinology 150:12 (2009), 5341–5350.
27. [27] Iizuka, K., Takeda, J., Horikawa, Y., Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Letters 583:17 (2009), 2882–2886.
28. [28] Chu, A.Y., Workalemahu, T., Paynter, N.P., Rose, L.M., Giulianini, F., Tanaka, T., et al. Novel locus including FGF21 is associated with dietary macronutrient intake. Human Molecular Genetics 22:9 (2013), 1895–1902.
29. [29] Tanaka, T., Ngwa, J.S., van Rooij, F.J., Zillikens, M.C., Wojczynski, M.K., Frazier-Wood, A.C., et al. Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake. American Journal of Clinical Nutrition 97:6 (2013), 1395–1402.
30. [30] Talukdar, S., Owen, B.M., Song, P., Hernandez, G., Zhang, Y., Zhou, Y., et al. FGF21 regulates sweet and alcohol preference. Cell Metabolism 23:2 (2016), 344–349.
31. [31] von Holstein-Rathlou, S., BonDurant, L.D., Peltekian, L., Naber, M.C., Yin, T.C., Claflin, K.E., et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metabolism 23:2 (2016), 335–343.
32. [32] Herman, M.A., Peroni, O.D., Villoria, J., Schon, M.R., Abumrad, N.A., Bluher, M., et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484:7394 (2012), 333–338.
33. [33] Dushay, J.R., Toschi, E., Mitten, E.K., Fisher, F.M., Herman, M.A., Maratos-Flier, E., Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Molecular Metabolism 4:1 (2015), 51–57.
34. [34] Fisher, F.M., Chui, P.C., Nasser, I.A., Popov, Y., Cunniff, J.C., Lundasen, T., et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology 147:5 (2014), 1073–1083 e6.
35. [35] Zavaroni, I., Chen, Y.D., Reaven, G.M., Studies of the mechanism of fructose-induced hypertriglyceridemia in the rat. Metabolism 31:11 (1982), 1077–1083.